Entrada Therapeutics, Inc. — Director's Dealing 2021

Nov 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-11-02

Reporting Person: Redmile Group, LLC (10% Owner)
Reporting Person: Green Jeremy (10% Owner)
Reporting Person: Redmile Biopharma Investments III, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Common Stock	C	954420	—	Acquired	954420	Indirect
2021-11-02	Common Stock	P	1000000	$20	Acquired	1954420	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Series B Convertible Preferred Stock	$	C	954420	Disposed		Common Stock (954420)	Indirect

Footnotes

F1: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F2: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: Reflects number of shares owned as of November 2, 2021.